Reviva Pharmaceuticals Holdings, Inc. (RVPH): Price and Financial Metrics


Reviva Pharmaceuticals Holdings, Inc. (RVPH): $1.71

-0.02 (-1.16%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RVPH to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

RVPH Stock Price Chart Interactive Chart >

Price chart for RVPH

RVPH Price/Volume Stats

Current price $1.71 52-week high $5.69
Prev. close $1.73 52-week low $1.34
Day low $1.69 Volume 5,000
Day high $1.79 Avg. volume 403,347
50-day MA $1.98 Dividend yield N/A
200-day MA $2.83 Market Cap 25.88M

Reviva Pharmaceuticals Holdings, Inc. (RVPH) Company Bio


Reviva Pharmaceuticals Holdings, Inc. operates as a clinical development pharmaceutical company. The Company focuses on developing a portfolio of internally discovered therapies that address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases. Reviva Pharmaceuticals Holdings serves customers worldwide.


RVPH Latest News Stream


Event/Time News Detail
Loading, please wait...

RVPH Latest Social Stream


Loading social stream, please wait...

View Full RVPH Social Stream

Latest RVPH News From Around the Web

Below are the latest news stories about Reviva Pharmaceuticals Holdings Inc that investors may wish to consider to help them evaluate RVPH as an investment opportunity.

Reviva Pharmaceuticals Announces First Patients Dosed in Pivotal Phase 3 Study and Long-Term Safety Trial Evaluating Brilaroxazine for the Treatment of Schizophrenia

- RECOVER is a Phase 3, randomized, double-blind study with registrational intent - - Reviva anticipates expanding the clinical development of brilaroxazine into other neuropsychiatric indications - CUPERTINO, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory di

Yahoo | February 1, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Grab a cup of coffee and get ready for another busy day of trading as we start with the biggest pre-market stock movers for Tuesday!

William White on InvestorPlace | January 11, 2022

RVPH: FDA Allows IND; Imminent Start to Phase III

By John Vandermosten, CFA NASDAQ:RVPH READ THE FULL RVPH RESEARCH REPORT FDA ‘Study May Proceed’ Letter Received Reviva Pharmaceutical Holdings, Inc. (NASDAQ:RVPH) announced on January 10, 2022 the receipt of a May Proceed letter from the FDA regarding pivotal Phase III clinical trials for brilaroxazine in schizophrenia, including one long-term safety trial. Through the letter, the FDA allowed

Yahoo | January 11, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Welcome back, trader!

William White on InvestorPlace | January 10, 2022

Reviva Pharmaceuticals Holdings, Inc. Receives FDA May Proceed Letter for Pivotal Phase 3 Clinical Trial and Long-Term Safety Trial Evaluating Brilaroxazine For The Treatment of Schizophrenia

- Brilaroxazine is a novel serotonin and dopamine receptor modulator currently being developed for diseases with dysfunctional serotonin signaling including neuropsychiatric and pulmonary indications - - Initiation of both Phase 3 trials is expected by end of January 2022 - CUPERTINO, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of

Yahoo | January 10, 2022

Read More 'RVPH' Stories Here

RVPH Price Returns

1-mo -19.34%
3-mo -13.20%
6-mo -54.76%
1-year -69.19%
3-year N/A
5-year N/A
YTD -40.83%
2021 -66.95%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7887 seconds.